Lopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children >6 months in the US and >2 years in the EU. Limited LPV paediatric pharmacokinetic data are available. We studied LPV pharmacokinetics to determine whether the recommended dose (230/57.5 mg/m2 twice daily) results in optimal LPV exposure in all age groups. Virological efficacy was a secondary objective.
Methods
HIV-1-infected children who started treatment with LPV/r and two nucleoside reverse transcriptase inhibitors underwent a 12-h pharmacokinetic curve. LPV plasma concentrations were determined with a validated HPLC method with UV detection. If Cmin was <1.0 mg/l LPV/r dose was increased by 33%. Plasma trough levels were drawn subsequently. HIV-1 RNA was followed-up until week 48.
Results
A total of 23 children were included (seven girls; 16 boys), with a median (range) age of 5.6 (0.4–13.2) years. Mean (±SD) AUC0–12h, Cmax and Cmin of LPV were 75.3 (±33.7) mg/l.h, 9.33 (±3.27) mg/l and 3.68 (±2.48) mg/l, respectively, which is similar to previously published data. Interindividual variability was large. Cmin was inadequate in 7/23 children. Significantly more children <2 years had inadequate Cmin compared with children >2 years. Dose increase to ±300/75 mg/m2 LPV/r led to Cmin >1.0 mg/l. The studied regimen provided excellent viral suppression for naive and pretreated patients.
Conclusions
Mean LPV pharmacokinetic parameters in these HIV-infected children are similar to published data, but exposure is significantly reduced in children <2 years. Prospective pharmacokinetic studies using 300/75 mg/m2 LPV/r in this age population are urgently warranted.
References
1.
Saez-LlorensX., ViolariA., DeetzC.O.Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.Pediatr Infect Dis J2003; 22: 216–224.
2.
RossoR., Di BiagioA., DentoneC.Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.J Antimicrob Chemother2006; 57: 1168–1171.
3.
van der LeeM., VerweelG., de GrootR., BurgerD.Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.Antivir Ther2006; 11: 439–445.
4.
DunnD.Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis.Lancet2003; 362: 1605–1611.
5.
SharlandM., BlancheS., CastelliG., RamosJ., GibbD.M.PENTA guidelines for the use of antiretroviral therapy, 2004.HIV Med2004; 5Suppl 2: 61–86.
6.
BergshoeffA.S., FraaijP.L., van RossumA.M.Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.Antivir Ther2003; 8: 215–222.
7.
FlorenL.C., WizniaA., HayashiS.Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.Pediatrics2003; 112: e220–e227.
8.
DrosteJ.A., Verweij-Van WissenC.P., BurgerD.M.Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.Ther Drug Monit2003; 25: 393–399.
9.
Anonymous.Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents, 2003. Available at: http://www.HIVpharmacology.com.
10.
AnanworanichJ., KosalaraksaP., HillA.Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.Pediatr Infect Dis J2005; 24: 974–979.
11.
GibaldiM.Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics.4th edition 1991; pp. 14–23Philadelphia and London: Lea & Febiger.
12.
The European Agency for the Evaluation of Medicinal Products.Summary of product characteristics Kaletra®. In Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Kaletra soft capsules, 2001; pp. 1–3.
13.
FraaijP.L., RakhmaninaN., BurgerD.M., de GrootR.Therapeutic drug monitoring in children with HIV/AIDS.Ther Drug Monit2004; 26: 122–126.
14.
KingJ.R., KimberlinD.W., AldrovandiG.M., AcostaE.P.Antiretroviral pharmacokinetics in the paediatric population: a review.Clin Pharmacokinet2002; 41: 1115–1133.
15.
WalmsleyS., BernsteinB., KingM.Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.N Engl J Med2002; 346: 2039–2046.
16.
RamosJ.T., De JoseM.I., DuenasJ.Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.Pediatr Infect Dis J2005; 24: 867–873.
17.
MurphyR.L., BrunS., HicksC.ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.AIDS2001; 15: F1–9.
18.
BongiovanniM., BiniT., AdorniF.Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Antivir Ther2003; 8: 209–214.
19.
BongiovanniM., ChiesaE., Di BiagioA.Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAARTJ Antimicrob Chemother2005; 55: 1003–1007.
20.
La PorteC.J.L., BackD.J., BlasckeT., BoucherC.A.B., FletcherC.V., FlexnerC.Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.Rev Antivir Ther2006; 3: 4–14.
21.
HsuA., IsaacsonJ., BrunS.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Antimicrob Agents Chemother2003; 47: 350–359.
22.
HoefnagelJ.G., Van der LeeM.J., KoopmansP.P.The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.AIDS2006; 20: 1069–1071.
23.
BreilhD., PellegrinI., RouzesA.Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).AIDS2004; 18: 1305–1310.
